2017 年第 2 期 第 15 卷

丝裂霉素联合吉西他滨对原发性肝癌患者外周血淋巴细胞亚群及NK?细胞活性的影响

作者：

单位：

关键词：原发性肝癌淋巴细胞亚群NK细胞丝裂霉素吉西他滨

• 摘要：
• 【摘要】[摘要]目的：探讨丝裂霉素联合吉西他滨对原发性肝癌患者外周血淋巴细胞亚群及NK细胞活性的影响。方法：收集2014年1月至2016年1月于我院就诊的原发性肝癌患者96例，按照分层随机分组法分作对照组和试验组，各48例，对照组予以吉西他滨治疗疗，试验组基于对照组联合丝裂霉素治疗，比较两组治疗后淋巴细胞亚群及NK细胞水平、临床疗效、不良反应。结果：治疗后，试验组淋巴细胞亚群及NK细胞水平优于对照组，比较有统计学差异（P<0.05）；试验组有效率高于对照组（P<0.05）；两组总不良反应率比较无统计学差异（P>0.05）。结论：原发性肝癌患者行丝裂霉素联合吉西他滨治疗能够有效调节外周血淋巴细胞亚群及NK细胞活性，缓解免疫抑制状态。
• To study The influence of peripheral blood lymphocyte subsets and NK cells activity by mitomycin in combination with gemcitabine in primary liver cancer. Methods: l 96 cases of patients with primary liver cancer were collected between January 2014 to January 2016 in our hospita, they were divided into control group and test group according to tStratified randomization method, each had 48 cases, ontrol group by gemcitabine treatmented, test group with based on the control group by mitomycin,two groups’ of lymphocyte subgroup and NK cell levels, clinical efficacy, adverse reactions after treatmented were compared. Results: After treatmented, the tset group lymphocyte subsets and NK cells level were better than that of control group, with statistical difference (P<0.05);test group effectiveness was higher than the control group (P<0.05); Two groups of total adverse reaction rate was no statistical difference (P>0.05). Conclusion: primary liver cancer patients with mitomycin and gemcitabine therapy can effectively adjust the peripheral blood lymphocyte subsets and NK cell activity, relieve immunosuppressive state.